Journal DOI 10.68956/dyh5-kwte

Creative Commons source reading · ALS and frontotemporal degeneration

Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study.

Ton Fang; Ahmad Al Khleifat; Jacques-Henri Meurgey; Ashley Jones; P Nigel Leigh; Gilbert Bensimon; Ammar Al-Chalabi

Originally published in The Lancet. Neurology · 2018-03-07

From the article

Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.

Abstract

Background Riluzole is the only drug to prolong survival for amyotrophic lateral sclerosis (ALS) and, at a dose of 100 mg, was associated with a 35% reduction in mortality in a clinical trial. A key question is whether the survival benefit occurs at an early stage of disease, late stage, or is spread throughout the course of the disease. To address this question, we used the King's clinical staging system to do a retrospective analysis of data from the original dose-ranging clinical trial of riluzole. Methods In the original dose-ranging trial, patients were enrolled between December, 1992, and November, 1993, in Belgium, France, Germany, Spain, Canada, the USA, and the UK if they had probable or definite ALS as defined by the El Escorial criteria. The censor date for the riluzole survival data was set as the original study end date of Dec 31, 1994. For this analysis, King's clinical ALS stage was estimated from the electronic case record data of the modified Norris scale, UK Medical Research Council score for muscle strength, El Escorial category, vital capacity, and gastrostomy insertion data.

Results

Combining treatment groups did not change these results. Analysing all treatment groups as a whole against placebo showed a significant prolongation of stage 4 in the treatment groups (HR 0·66, 95% CI 0·48–0·91; p=0·01), as did limiting the analysis to the two higher doses against placebo (figure 2), but there was no prolongation for other stages (figure 2).

Discussion

Treatment with riluzole prolonged stage 4 in patients with ALS. This result was robust to the method of analysis and independent of the stage at which treatment was started. This finding implies that the survival benefit of riluzole is achieved by extending stage 4, not by prolonging stages 2 or 3, or generally slowing disease.

Editorial reading guide

  • Was the evidence cross-sectional, longitudinal or experimental?
  • How did the authors account for age, disease stage and differences among participants?